"Our first paper was a proof-of-concept lipid nanoparticle design," says Michael J. Mitchell, Associate Professor in ...

Berndsen handed the data off to Keith Cassidy, another new professor, who focuses on simulation. “AlphaFold frankly can’t ...

CBX-12 is under clinical development by Cybrexa and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition ...

“Our first paper was a proof-of-concept lipid nanoparticle design,” says Michael J. Mitchell, Associate Professor in Bioengineering (BE) and the paper’s senior author. “It was like showing we could ...

Testing the Concept To confirm the peptides were functioning as intended, the researchers first needed to verify they adhered to the LNPs. "Our LNPs are a complex mixture of nucleic acids, lipids ...

Retatrutide, a synthetic peptide with unique properties, has recently gained attention for its multifunctional roles and the ...

“Our first paper was a proof-of-concept lipid nanoparticle design,” says Michael J. Mitchell, Associate Professor in Bioengineering (BE) and the paper’s senior author. “It was like showing we could ...

His solution? The Triple-Lipid Peptide Cream from Skinfix. Unsolicited though it was, his advice turned out to be an absolute godsend for the rough texture I’ve struggled with every winter.